Umbilical cord stem cells hold promise as a therapy for Crohn’s disease, a chronic condition characterized by inflammation in various parts of the digestive tract. It affects approximately 1 in every 300 people in the UK and manifests with symptoms like severe abdominal pain, diarrhea, fatigue, loss of appetite, and sometimes anemia. While the exact causes of Crohn’s disease remain unknown, factors such as genetic predisposition, immune system dysfunction, gut microbiota imbalance, and environmental influences like stress and smoking are believed to play a role.

Unfortunately, there is currently no cure for Crohn’s disease, and existing treatments primarily focus on managing symptoms, with limited success rates. Given the challenges in treating Crohn’s disease, there is a pressing need for innovative therapeutic approaches. Recently, researchers have turned their attention to umbilical cord stem cells as a potential treatment option.

A study published in the journal eBioMedicine conducted a clinical trial to explore the efficacy of umbilical cord mesenchymal stem cells (UC-MSCs) in treating Crohn’s disease. The trial, conducted between November 2020 and October 2023, involved 17 patients with moderate to severe Crohn’s disease who had not responded to conventional treatment.

During the trial, patients received injections of UC-MSCs via colonoscopy and intravenous drip. Over the course of 24 weeks, researchers monitored the patients’ progress, assessing both laboratory markers and clinical outcomes. The results were promising, with eight patients showing improvement in their Simple Endoscopic Score for Crohn’s disease (SES-CD) scores, indicating a reduction in ulcer size and severity. Additionally, three patients achieved mucosal healing, with their SES-CD scores reaching zero. By the end of the trial, all patients had achieved clinical remission.

In addition to evaluating the therapeutic effects of UC-MSCs, researchers sought to understand the underlying mechanism of action. Biopsies of intestinal mucosa were taken from three patients before and after the trial for transcriptome sequencing analysis.

The analysis revealed that UC-MSCs upregulated the expression of genes involved in maintaining the integrity of the intestinal epithelial barrier while downregulating genes associated with inflammation. Essentially, this suggests that UC-MSCs help inhibit the inflammatory response and improve the integrity of the intestinal barrier, addressing key aspects of Crohn’s disease pathophysiology.

Although the clinical trial had limitations in terms of size and scope, the findings provide valuable insights into the potential of umbilical cord stem cells as a treatment for Crohn’s disease. Moving forward, further research is needed to validate these results and explore the long-term efficacy and safety of UC-MSC therapy.

In conclusion, the study offers hope for individuals living with Crohn’s disease by introducing a novel approach to treatment. By harnessing the regenerative properties of umbilical cord stem cells, researchers may have discovered a promising avenue for managing this debilitating condition.

If you’re interested in learning more about umbilical cord and placental stem cells and how they could benefit your baby, sign up below for a free welcome pack or speak to on our our specialists at +97143116613.